Oxaliplatin (Standard), CAS 61825-94-3

Oxaliplatin (Standard), CAS 61825-94-3
SKU
MEXHY-17371R-25
Packaging Unit
25 mg
Manufacturer
MedChemExpress

Availability: loading...
Price is loading...
Product Description: Oxaliplatin (Standard) is the analytical standard of Oxaliplatin. This product is intended for research and analytical applications. Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research[1][2][3].

Formula: N/A

References: [1]Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71./[2]Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63./[3]Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6./[4]Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604/[5]Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43(4):237-50./[6]Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20./[7]Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92./[8]Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40./[9]Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347.

CAS Number: 61825-94-3

Molecular Weight: N/A

Research Area: Cancer

Target: Apoptosis;DNA/RNA Synthesis
More Information
SKU MEXHY-17371R-25
Manufacturer MedChemExpress
Manufacturer SKU HY-17371R-25
Green Labware No
Package Unit 25 mg
Quantity Unit STK
Product information (PDF) Download
MSDS (PDF)
×